Oculis Holding Announces Phase III Failure of Lead Candidate OCS-01 in Diabetic Macular Edema, Abandons FDA Filing

(Source: Yidu Medicine)

On May 29, 2026, Swiss biopharmaceutical company Oculis Holding (NASDAQ: OCS) announced that its two Phase III clinical trials (DIAMOND-1/2) of the core pipeline candidate OCS-01 eye drops for the treatment of diabetic macular edema (DME) failed to meet their primary endpoints.The stock price plummeted 23.42% in response, closing at $22.70, with an intraday drop exceeding 45%, wiping out over $400 million in market capitalization.

Highly Concentrated Pipeline: Clinical Failures Trigger Sharp Decline

Oculis is a global biopharmaceutical company headquartered in Switzerland, with operations in the United States, Iceland, and Switzerland. The company specializes in the research and development of novel therapeutics for ophthalmology and neuro-ophthalmology.

The DIAMOND program, which recently failed, was a blockbuster bet by Oculis, comprisingTwo global, multicenter, randomized, double-blind Phase III trials involving 119 study centers and over 800 patients with diabetic macular edema (DME), with a treatment duration of 52 weeks.

The primary endpoint of this study is the mean change from baseline in best-corrected visual acuity (BCVA) at Week 52 (an industry-recognized core efficacy endpoint); secondary endpoints include reduction in retinal thickness and the proportion of patients with a visual acuity improvement of ≥15 letters, among others.

The core of the failure lies in the fact that neither trial met the primary endpoint of best-corrected visual acuity (BCVA) improvement, indicating that OCS-01 failed to significantly enhance patients’ vision. Although the drug significantly reduced retinal thickness (indicating improvement in edema), this anatomical benefit did not translate into clinical visual gains. Furthermore, the key secondary endpoint of “visual acuity improvement of ≥15 letters” was also not met, completely ruling out any possibility of regulatory approval through remedial measures.

Oculis Officially Confirms,No further pursuit of the FDA marketing application for OCS-01 in DME; commercialization expectations for the core pipeline may drop directly to zero.CEO Riad Sherif candidly stated, “We are deeply disappointed that the improvement in retinal thickness did not translate into visual benefits.”

It is worth noting that OCS-01 is Oculis’s only commercial candidate to have entered Phase III clinical trials. Previously regarded as the world’s first topical eye drop for diabetic macular edema (DME), it has the potential to disrupt existing injection-based therapies, a market valued at over $3 billion. Prior to its launch, investment banks such as Guggenheim assigned an exceptionally high target price of $75, based on the core rationale that OCS-01 could address the unmet needs of more than 1 million patients.

Beyond OCS-01, Oculis has only two early-stage assets (Privosegtor for optic neuropathy and Licaminlimab for dry eye disease), with no near-term pipeline candidates to sustain its valuation.

The core of DME treatment is to improve vision; merely reducing edema without enhancing visual acuity renders its clinical value null, with no payers willing to cover the cost.Furthermore, although no serious adverse reactions were disclosed, the mechanistic contradiction that anatomical efficacy ≠ visual benefit has raised questions about the drug’s long-term safety and mechanism of action.

Current standard therapies for DME (such as anti-VEGF injections) can steadily improve vision, whereas OCS-01 offers no advantages in comparison, resulting in a complete loss of market competitiveness.

Following clinical failure, Oculis may be unable to replenish its cash flow through equity financing in the near term. Although the company’s existing cash reserves can sustain operations until 2029, its growth narrative is temporarily halted.

Meanwhile, this failure has intensified market skepticism about the potential of innovative ophthalmic eye drops to replace injection-based therapies, putting pressure on the valuations of similar projects in development.

Company Makes Emergency Cutbacks to Survive, Bets on New Pipeline

In the announcement, Oculis stated that it would redirect all R&D and financial resources toward Privosegtor (optic neuropathy) and Licaminlimab (dry eye disease), while suspending all further development of OCS-01.

Among them, Privosegtor, indicated for the treatment of optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION), has received FDA Breakthrough Therapy Designation and European PRIME designation, with a U.S. market size exceeding $7 billion.

Licaminlimab is an anti-TNFα eye drop for dry eye disease. Phase II trials showed a 5- to 7-fold increase in efficacy in patients with specific genotypes, highlighting its significant potential for precision medicine.

As of March 31, 2026, Oculis held $277.6 million in cash and short-term investments, sufficient to fund operations through the second half of 2029 without the need for emergency financing, thereby buying time for its pipeline transformation.

Prior to the recent sharp decline in its stock price, Oculis was highly favored in the capital markets, buoyed by its strong fundamentals and industry prestige.

Leveraging its proprietary solubilizing nanoparticle (SNP) technology platform, the company focuses on the research and development of ophthalmic drugs for topical and nasal administration, aiming to replace intravitreal injections—the current clinical standard—with non-invasive drug delivery methods. Its core product, OCS-01, is positioned for the treatment of diabetic macular edema and for anti-inflammatory and analgesic management following cataract surgery. This differentiated technological advantage has successfully attracted investment from leading institutions such as Novartis Venture Fund and Tekla Capital, while multiple Wall Street research reports have consistently maintained optimistic ratings.

Investment in the biopharmaceutical industry inherently carries high risk. No matter how compelling the business narrative or how robust the capital backing, rigorous clinical data must serve as the ultimate benchmark. The failure of this Phase III clinical trial has directly undermined the core logic underpinning the company’s foundation, prompting the market to reassess its future growth potential.

Oculis’s ordeal offers multiple warnings to investors in the pharmaceutical sector—first, clinical data is the lifeline. The value of clinical-stage biotech companies is entirely tied to pipeline progress; hype cannot withstand the impact of clinical results.

Secondly, mitigate the risks associated with a single-product pipeline. Companies that rely excessively on a single core drug often experience a cliff-like drop in valuation when R&D efforts fail.

More notably,Objectively consider institutional viewpoints. Institutional ratings are for reference only; in the face of substantive negative news such as R&D failures, previously optimistic expectations can quickly become invalid.

Source: Oculis Official Announcement